Those aspiring to outpace the market meticulously engage in the process of selecting individual stocks. Strategic choices can be instrumental in accelerating your wealth.
After finishing at $5.86 in the prior trading day, Ocular Therapeutix Inc (NASDAQ: OCUL) closed at $5.22, down -10.92%. In other words, the price has decreased by -$10.92 from its previous closing price. On the day, 9.12 million shares were traded. OCUL stock price reached its highest trading level at $5.9 during the session, while it also had its lowest trading level at $4.98.
Ratios:
Our goal is to gain a better understanding of OCUL by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 6.59 and its Current Ratio is at 6.66. In the meantime, Its Debt-to-Equity ratio is 0.92 whereas as Long-Term Debt/Eq ratio is at 0.90.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, BofA Securities on February 09, 2024, initiated with a Buy rating and assigned the stock a target price of $15.
On April 21, 2023, Robert W. Baird started tracking the stock assigning a Outperform rating and target price of $18.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Feb 26 ’24 when SUMMER ROAD LLC bought 930,851 shares for $7.52 per share. The transaction valued at 7,000,000 led to the insider holds 8,591,401 shares of the business.
Mattessich Antony C. sold 18,338 shares of OCUL for $90,773 on Jan 31 ’24. The President and CEO now owns 427,943 shares after completing the transaction at $4.95 per share. On Jan 31 ’24, another insider, Ozden Rabia Gurses, who serves as the Chief Medical Officer of the company, sold 7,764 shares for $4.95 each. As a result, the insider received 38,432 and left with 92,767 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, OCUL now has a Market Capitalization of 775832960 and an Enterprise Value of 663417216. For the stock, the TTM Price-to-Sale (P/S) ratio is 13.28 while its Price-to-Book (P/B) ratio in mrq is 6.59. Its current Enterprise Value per Revenue stands at 11.352 whereas that against EBITDA is -8.355.
Stock Price History:
Over the past 52 weeks, OCUL has reached a high of $11.31, while it has fallen to a 52-week low of $2.00. The 50-Day Moving Average of the stock is -39.47%, while the 200-Day Moving Average is calculated to be 6.11%.
Shares Statistics:
The stock has traded on average 2.15M shares per day over the past 3-months and 2691910 shares per day over the last 10 days, according to various share statistics. A total of 148.63M shares are outstanding, with a floating share count of 135.05M. Insiders hold about 9.13% of the company’s shares, while institutions hold 45.02% stake in the company. Shares short for OCUL as of 1711584000 were 11808322 with a Short Ratio of 5.48, compared to 1709164800 on 4739367. Therefore, it implies a Short% of Shares Outstanding of 11808322 and a Short% of Float of 8.3100006.
Earnings Estimates
Ocular Therapeutix Inc (OCUL) is presently subject to a detailed evaluation by Oaktree Specialty Lending Corpo analysts, each offering their unique perspectives on its market standing.The consensus estimate for the next quarter is $5.22, with high estimates of $11.78 and low estimates of $1.66.
